Learning Objectives: -Summarize guideline updates and clinical evidence supporting the use of upfront and sequential BTKi options, BCL2i platforms, and emerging targeted and immune-based modalities in CLL -Develop personalized frontline treatment plans featuring BTKi or BCL2i options, including continuous or fixed-duration platforms, for patients with CLL -Employ sequential treatment strategies utilizing targeted or immunotherapy options for relapsed/refractory CLL, including for patients with BTKi and/or BCL2i-exposed disease -Utilize team care delivery strategies to ensure adequate dosing, safety management and treatment planning for patients with treatment naïve or relapsed/refractory CLL receiving care with newer therapeutics
- Provider:Medical Learning Institute, Inc.
- Activity Link: https://PeerView.com/THK
- Start Date: 2024-09-04 05:00:00
- End Date: 2024-09-04 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABIM - 1.0 Point; Credit Type(s): Patient Safety (ABIM) - Commercial Support: Source: AbbVie (Any division) - Amount: 2860.0 - Is Kind Support: False Source: AstraZeneca (Any division) - Amount: 14301.0 - Is Kind Support: False Source: BeiGene - Amount: 23834.0 - Is Kind Support: False Source: Janssen (Any division) - Amount: 18877.0 - Is Kind Support: False Source: Lilly (Any division) - Amount: 28410.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Internal Medicine, Medical Oncology
Subscribe
Login
0 Comments
Oldest